Michel Dib

Summary

Country: France

Publications

  1. ncbi request reprint Issues for clinical drug development in neurodegenerative diseases
    Michel Dib
    Service de Neurologie, Hopital de la Salpetriere, Paris, France
    Drugs 65:2463-79. 2005
  2. ncbi request reprint [What are the etiological medical therapies in amyotrophic lateral sclerosis?]
    M Dib
    Fédération des Maladies du Système Nerveux, Hopital de la Pitie Salpetriere, 75651 Paris Cedex 13
    Rev Neurol (Paris) 162:4S215-4S219. 2006
  3. doi request reprint Biomarkers in amyotrophic lateral sclerosis: facts and future horizons
    Pierre Francois Pradat
    Assistance Publique Hopitaux de Paris, Fédération des Maladies du Système Nerveux, Centre référent maladie rare SLA, Hopital de la Pitie Salpetriere, Paris, France
    Mol Diagn Ther 13:115-25. 2009
  4. ncbi request reprint Amyotrophic lateral sclerosis: progress and prospects for treatment
    Michel Dib
    Laboratoire Aventis, Paris, France
    Drugs 63:289-310. 2003
  5. ncbi request reprint Annual rate and predictors of conversion to dementia in subjects presenting mild cognitive impairment criteria defined according to a population-based study
    Helene Amieva
    INSERM Unit 593, Universite Victor Segalen, Bordeaux, France
    Dement Geriatr Cogn Disord 18:87-93. 2004
  6. ncbi request reprint Neuroprotective effect of riluzole in acute noise-induced hearing loss
    Jérôme Ruel
    Inserm U 583 et Université Montpellier 1 Hôpital Saint Eloi, 34090 Montpellier Cedex 5, France
    Neuroreport 16:1087-90. 2005
  7. ncbi request reprint Can malondialdehyde be used as a biological marker of progression in neurodegenerative disease?
    Michel Dib
    Laboratoire Aventis, 46, quai de la Râpée, 75601 Paris Cedex 12, France
    J Neurol 249:367-74. 2002
  8. ncbi request reprint Riluzole in Huntington's disease: a 3-year, randomized controlled study
    G Bernhard Landwehrmeyer
    Department of Neurology, University of Ulm, Ulm, Germany
    Ann Neurol 62:262-72. 2007
  9. doi request reprint Mutations of the ANG gene in French patients with sporadic amyotrophic lateral sclerosis
    Agathe Paubel
    INSERM U930, Université François Rabelais Tours, CHRU de Tours, Faculte de Medecine, 10 boulevard Tonnelle, BP3223, 37032 Tours Cedex, France
    Arch Neurol 65:1333-6. 2008
  10. ncbi request reprint Glutamate levels in cerebrospinal fluid in amyotrophic lateral sclerosis: a reappraisal using a new HPLC method with coulometric detection in a large cohort of patients
    Odile Spreux-Varoquaux
    Service de Biochimie Pharmacologie et d Anesthésie, Hopital de Versailles, Le Chesnay, France
    J Neurol Sci 193:73-8. 2002

Collaborators

  • Pierre Francois Pradat
  • V Meininger
  • Philippe Couratier
  • A C Ludolph
  • Gilbert Bensimon
  • Jérôme Ruel
  • Agathe Paubel
  • G Bernhard Landwehrmeyer
  • Francois Salachas
  • Helene Amieva
  • Odile Spreux-Varoquaux
  • Alain Destee
  • Gwendal Lemasson
  • Christophe Vial
  • Marie Helene Soriani
  • Fredric Dubas
  • Maïté Amy
  • Emmanuel Broussole
  • Nadia Vandenberghe
  • Laurence Carluer
  • Nicholas Pageot
  • Pierre Clavelou
  • Patrick Vourc'h
  • Pascal Cintas
  • Cecile Maugras
  • Jean Christophe Antoine
  • Christian R Andres
  • Emmanuelle Salort
  • Fausto Viader
  • Philippe Corcia
  • Dominique Lardiller
  • Nadine Leforestier
  • Guillaume Garrigues
  • Veronique Danel
  • Christine Tranchant
  • Claude Desnuelle
  • Maurice Giroud
  • Jean Pouget
  • Annie Verschuren
  • Julien Praline
  • William Camu
  • Jean Philippe Camdessanche
  • Gerard Besson
  • Guillaume Nicolas
  • Marie Christine Arne-Bes
  • Gaelle Bruneteau
  • Marc Debouverie
  • Jeremy Violette
  • Nathalie Guy
  • Marie Celine Fleury
  • Matthieu Lacoste
  • Sophie Pition
  • Wilhelm Fischer
  • Horst Przuntek
  • Justo Garcia de Yebenes
  • Adam Doble
  • Peter H Kraus
  • Bruno Dubois
  • Wilhelm Gaus
  • Berry Kremer
  • Luc Letenneur
  • Pascale Barberger-Gateau
  • Christophe Sourgen
  • Isabelle Rouch-Leroyer
  • Jean Marc Orgogozo
  • Colette Fabrigoule
  • Françoise D'Alchée-Birée
  • Jean Francois Dartigues
  • Abdellatif Marouan
  • Nadine Le Forestier
  • Lucette Lacomblez

Detail Information

Publications10

  1. ncbi request reprint Issues for clinical drug development in neurodegenerative diseases
    Michel Dib
    Service de Neurologie, Hopital de la Salpetriere, Paris, France
    Drugs 65:2463-79. 2005
    ....
  2. ncbi request reprint [What are the etiological medical therapies in amyotrophic lateral sclerosis?]
    M Dib
    Fédération des Maladies du Système Nerveux, Hopital de la Pitie Salpetriere, 75651 Paris Cedex 13
    Rev Neurol (Paris) 162:4S215-4S219. 2006
    ..Different new methods, as the cellular therapy are in development, and represent a real hope for the future...
  3. doi request reprint Biomarkers in amyotrophic lateral sclerosis: facts and future horizons
    Pierre Francois Pradat
    Assistance Publique Hopitaux de Paris, Fédération des Maladies du Système Nerveux, Centre référent maladie rare SLA, Hopital de la Pitie Salpetriere, Paris, France
    Mol Diagn Ther 13:115-25. 2009
    ..This article provides an overview of recently described biologic and radiologic markers of the disease...
  4. ncbi request reprint Amyotrophic lateral sclerosis: progress and prospects for treatment
    Michel Dib
    Laboratoire Aventis, Paris, France
    Drugs 63:289-310. 2003
    ..For this reason, surrogate markers that can be used for rapid screening in patients of potential treatments identified in the transgenic mice are urgently needed...
  5. ncbi request reprint Annual rate and predictors of conversion to dementia in subjects presenting mild cognitive impairment criteria defined according to a population-based study
    Helene Amieva
    INSERM Unit 593, Universite Victor Segalen, Bordeaux, France
    Dement Geriatr Cogn Disord 18:87-93. 2004
    ..Among the variables considered, the Letter Cancellation Test proved to be a major predictor of short-term conversion to dementia...
  6. ncbi request reprint Neuroprotective effect of riluzole in acute noise-induced hearing loss
    Jérôme Ruel
    Inserm U 583 et Université Montpellier 1 Hôpital Saint Eloi, 34090 Montpellier Cedex 5, France
    Neuroreport 16:1087-90. 2005
    ....
  7. ncbi request reprint Can malondialdehyde be used as a biological marker of progression in neurodegenerative disease?
    Michel Dib
    Laboratoire Aventis, 46, quai de la Râpée, 75601 Paris Cedex 12, France
    J Neurol 249:367-74. 2002
    ..This will allow a clearer picture to emerge as to whether malondialdehyde can be considered as a marker for the evolution of these diseases...
  8. ncbi request reprint Riluzole in Huntington's disease: a 3-year, randomized controlled study
    G Bernhard Landwehrmeyer
    Department of Neurology, University of Ulm, Ulm, Germany
    Ann Neurol 62:262-72. 2007
    ..We conducted a randomized double-blind trial of riluzole in Huntington's disease to investigate the efficacy of this antiexcitotoxic drug in slowing disease progression...
  9. doi request reprint Mutations of the ANG gene in French patients with sporadic amyotrophic lateral sclerosis
    Agathe Paubel
    INSERM U930, Université François Rabelais Tours, CHRU de Tours, Faculte de Medecine, 10 boulevard Tonnelle, BP3223, 37032 Tours Cedex, France
    Arch Neurol 65:1333-6. 2008
    ..However, the cellular and molecular mechanisms that link ANG, a multidomain protein, to ALS are still unknown...
  10. ncbi request reprint Glutamate levels in cerebrospinal fluid in amyotrophic lateral sclerosis: a reappraisal using a new HPLC method with coulometric detection in a large cohort of patients
    Odile Spreux-Varoquaux
    Service de Biochimie Pharmacologie et d Anesthésie, Hopital de Versailles, Le Chesnay, France
    J Neurol Sci 193:73-8. 2002
    ..It remains to be determined if the group of patients with high CSF glutamate concentrations represents a specific subgroup of patients in terms of mechanism of disease, or only in terms of the spatial extent of motor neuron insult...